Table 2 Antibiogram of ESBL producing E. coli isolates from different sources
Number of isolates susceptible (% susceptibility) | |||||
|---|---|---|---|---|---|
Source | Human case (n = 18) | Human control (n = 10) | Poultry (n = 36) | Environment (n = 36) | Total (n = 100) |
Antibiotics tested | |||||
Amoxicillin/Clavulanate | 10 (56%) | 10 (100%) | 28 (78%) | 33 (92%) | 81 (81%) |
Piperacillin/Tazobactam | 13(72) | 10 (100%) | 35 (97%) | 32 (89%) | 90 (90%) |
Cefepime | 8 (44%) | 3(30%) | 13 (36%) | 6 (17%) | 30 (30%) |
Imipenem | 16 (89%) | 10 (100%) | 36 (100%) | 36 (100%) | 98 (98%) |
Meropenem | 15 (83%) | 10 (100%) | 34 (94%) | 35 (97%) | 94 (94%) |
Amikacin | 17 (94%) | 10 (100%) | 32(89%) | 34 (94%) | 93 (93%) |
Gentamicin | 13 (72%) | 10 (100%) | 24 (67%) | 33(92%) | 80 (80%) |
Ciprofloxacin | 1 (6%) | 3(30%) | 2(6%) | 2(6%) | 8 (8%) |
Tigecycline | 17 (94%) | 10 (100%) | 31 (96%) | 36 (100%) | 94(94%) |
Cotrimoxazole | 3(17%) | 7 (70%) | 14 (39%) | 23(64%) | 47 (47%) |